Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 645
- 试验地点
- 1
- 主要终点
- Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score
研究概览
简要总结
To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.
To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion > 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions < 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.
排除标准
- •Patients below 18 years old.
- •Patients with pre-existing other malignancies.
- •Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases.
- •Patients with pre-existing haematologic disorders.
- •Patients with proteinuria.
- •Missed follow-up.
结局指标
主要结局
Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score
时间窗: 2 years
We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score
时间窗: 2 years
We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores
次要结局
- Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score(2 years)
- Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)(2 years)
研究者
Ahmed Abudeif Abdelaal, MD
Principal investigator
Sohag University
